局部晚期鼻咽癌的化疗研究进展
Research Progress of Chemotherapy for Locally Advanced Nasopharyngeal Carcinoma
DOI: 10.12677/acm.2025.15113173, PDF,   
作者: 叶自钊, 冯 成, 韦世鑫：右江民族医学院附属西南医院，广西 百色；杨开炎：百色市人民医院耳鼻咽喉头颈外科，广西 百色；韦福依*：百色市中医医院耳鼻咽喉科，广西 百色
关键词: 鼻咽癌；诱导化疗；同步放化疗；辅助化疗；Nasopharyngeal Carcinoma； Induction Chemotherapy； Concurrent Chemoradiotherapy； Adjuvant Chemotherapy
摘要: 鼻咽癌在我国东南地区是一种常见的恶性肿瘤，大多数患者确诊时已经是局部晚期。鼻咽癌手术治疗受到限制，但对放化疗比较敏感。诱导化疗具有较高的化疗后缓解率、消灭微转移病灶、明显降低肿瘤负荷、良好的依从性及耐受性等优势而备受关注。辅助化疗也具有一定疗效，但因为患者耐受性差、临床价值不确定而越来越受到质疑。本文综述了关于局部晚期鼻咽癌的化疗方式研究进展，为临床工作中提供治疗参考。
Abstract: Nasopharyngeal carcinoma (NPC) is a common malignant tumor in southeast China, and most patients are diagnosed at a locally advanced stage. The surgical treatment of nasopharyngeal carcinoma is limited, but it is sensitive to radiotherapy and chemotherapy. Induction chemotherapy has attracted much attention due to its high remission rate after chemotherapy, eradication of micrometastatic lesions, significant reduction in tumor burden, good compliance and tolerance. Adjuvant chemotherapy is also effective, but it is increasingly questioned because of poor tolerance and uncertain clinical value. This article reviews the research progress of chemotherapy methods for locally advanced nasopharyngeal carcinoma, so as to provide treatment reference for clinical work.
文章引用：叶自钊, 冯成, 韦世鑫, 杨开炎, 韦福依. 局部晚期鼻咽癌的化疗研究进展[J]. 临床医学进展, 2025, 15(11): 894-900. https://doi.org/10.12677/acm.2025.15113173

参考文献

[1] Su, L., She, L. and Shen, L. (2021) The Current Role of Adjuvant Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma. Frontiers in Oncology, 10, Article ID: 585046. [Google Scholar] [CrossRef] [PubMed]
[2] 中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会. 中国鼻咽癌放射治疗指南(2020版) [J]. 中华肿瘤防治杂志, 2021, 28(3): 167-177.
[3] 周勇, 陈浩, 窦前, 等. 基于5种EB病毒抗体评估广州地区人群患鼻咽癌的危险度[J]. 实用医学杂志, 2023, 39(5): 602-606, 612.
[4] Jiromaru, R., Nakagawa, T. and Yasumatsu, R. (2022) Advanced Nasopharyngeal Carcinoma: Current and Emerging Treatment Options. Cancer Management and Research, 14, 2681-2689. [Google Scholar] [CrossRef] [PubMed]
[5] 王颖, 刘淑君, 邹怡华, 等. F-NLR评分对局部晚期鼻咽癌预后的影响[J]. 医学研究杂志, 2023, 52(4): 122-127.
[6] 金鑫. 局部晚期鼻咽癌TPF方案诱导化疗后同期放化疗与序贯单纯放疗的疗效及预后比较[D]: [硕士学位论文]. 桂林: 桂林医学院, 2023.
[7] 蒋朝阳, 王娟, 陈治明, 等. 局部T晚期与N晚期鼻咽癌患者的预后比较[J]. 中国肿瘤临床, 2020, 47(15): 780-783.
[8] 蒋婷婷, 李和沛, 王丹, 等. CTCs和CTMs在局部晚期鼻咽癌预后判断中的临床应用[J]. 西部医学, 2023, 35(2): 214-218, 222.
[9] Zhu, F., Wu, Y. and Wang, H. (2023) Advance in Integrating Platinum-Based Chemotherapy with Radiotherapy for Locally Advanced Nasopharyngeal Carcinoma. Frontiers in Oncology, 13, Article ID: 1259331. [Google Scholar] [CrossRef] [PubMed]
[10] Xie, R., Xia, B., Zhang, X., Hu, W., Zhao, R., Xie, C., et al. (2016) T4/N2 Classification Nasopharyngeal Carcinoma Benefit from Concurrent Chemotherapy in the Era of Intensity-Modulated Radiotherapy. Oncotarget, 7, 81918-81925. [Google Scholar] [CrossRef] [PubMed]
[11] Yin, L., Bian, X., Wang, X., Chen, M., Wu, J., Xu, J., et al. (2015) Long-Term Results of Concurrent Chemoradiotherapy for Advanced N2-3 Stage Nasopharyngeal Carcinoma. PLOS ONE, 10, e0137383. [Google Scholar] [CrossRef] [PubMed]
[12] 黄超, 梁祖君, 赵耀, 等. 铂基抗癌药物与蛋白质配位键相互作用质谱研究新进展[J]. 质谱学报, 2021, 42(5): 819-844.
[13] Tang, L., Chen, Y., Chen, C., Chen, M., Chen, N., Chen, X., et al. (2021) The Chinese Society of Clinical Oncology (CSCO) Clinical Guidelines for the Diagnosis and Treatment of Nasopharyngeal Carcinoma. Cancer Communications, 41, 1195-1227. [Google Scholar] [CrossRef] [PubMed]
[14] 李光烈, 徐西伟, 王思阳. 局部中晚期鼻咽癌诱导化疗后放疗开始时间与预后相关[J]. 中华放射肿瘤学杂志, 2023, 32(12): 1037-1043.
[15] Wang, B., Xiao, B., Lin, G., Wang, C. and Liu, Q. (2020) The Efficacy and Safety of Induction Chemotherapy Combined with Concurrent Chemoradiotherapy versus Concurrent Chemoradiotherapy Alone in Nasopharyngeal Carcinoma Patients: A Systematic Review and Meta-Analysis. BMC Cancer, 20, Article No. 393. [Google Scholar] [CrossRef] [PubMed]
[16] Meng, Y., Huang, C. and Huang, W. (2023) Survival after Induction Chemotherapy in Locoregional Advanced Nasopharyngeal Carcinoma: An Updated Systematic Review and Meta‐Analysis. Laryngoscope Investigative Otolaryngology, 8, 1217-1225. [Google Scholar] [CrossRef] [PubMed]
[17] Ribassin-Majed, L., Marguet, S., Lee, A.W.M., Ng, W.T., Ma, J., Chan, A.T.C., et al. (2017) What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis. Journal of Clinical Oncology, 35, 498-505. [Google Scholar] [CrossRef] [PubMed]
[18] Chen, Y., Tang, L., Yang, Q., Poh, S., Hui, E.P., Chan, A.T.C., et al. (2018) Induction Chemotherapy Plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized Trials. Clinical Cancer Research, 24, 1824-1833. [Google Scholar] [CrossRef] [PubMed]
[19] Pfister, D.G., Ang, K., Brizel, D.M., Burtness, B.A., Busse, P.M., Caudell, J.J., et al. (2013) Head and Neck Cancers, Version 2.2013. Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network, 11, 917-923. [Google Scholar] [CrossRef] [PubMed]
[20] Zeng, Z., Yan, R., Tu, L., Wang, Y., Chen, P., Luo, F., et al. (2018) Assessment of Concurrent Chemoradiotherapy plus Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: Cisplatin, Fluorouracil, and Docetaxel versus Gemcitabine and Cisplatin. Scientific Reports, 8, Article No. 15581. [Google Scholar] [CrossRef] [PubMed]
[21] Wang, F.Z., et al. (2020) Optimal Induction Chemotherapeutic Regimen Followed by Concurrent Chemotherapy plus Intensity-Modulated Radiotherapy as First-Line Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma. Medicine, 99, e22283. [Google Scholar] [CrossRef] [PubMed]
[22] Xu, G., Wang, Q., Wu, X., Lv, C., Zeng, G., Xue, Z., et al. (2021) Comparison of Induction Chemotherapy plus Concurrent Chemoradiotherapy and Concurrent Chemoradiotherapy Alone in Locally Advanced Nasopharyngeal Carcinoma. Technology in Cancer Research & Treatment, 20. [Google Scholar] [CrossRef] [PubMed]
[23] Tao, H., Zhan, Z., Qiu, W., Liao, K., Yuan, Y. and Zheng, R. (2021) Docetaxel and Cisplatin Induction Chemotherapy with or without Fluorouracil in Locoregionally Advanced Nasopharyngeal Carcinoma: A Retrospective Propensity Score Matching Analysis. Asia-Pacific Journal of Clinical Oncology, 18, e111-e118. [Google Scholar] [CrossRef] [PubMed]
[24] Zhang, Y., Chen, L., Hu, G., Zhang, N., Zhu, X., Yang, K., et al. (2019) Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. New England Journal of Medicine, 381, 1124-1135. [Google Scholar] [CrossRef] [PubMed]
[25] Lee, N., Harris, J., Garden, A.S., Straube, W., Glisson, B., Xia, P., et al. (2009) Intensity-Modulated Radiation Therapy with or without Chemotherapy for Nasopharyngeal Carcinoma: Radiation Therapy Oncology Group Phase II Trial 0225. Journal of Clinical Oncology, 27, 3684-3690. [Google Scholar] [CrossRef] [PubMed]
[26] Wang, L., Wu, Z., Cheng, W., Xie, D., Lin, F., Xia, L., et al. (2021) Efficacy of Concurrent Chemoradiotherapy in Subgroups of Stage III Nasopharyngeal Carcinoma: An Analysis Based on 10-Year Follow-up. Radiation Oncology, 16, Article No. 215. [Google Scholar] [CrossRef] [PubMed]
[27] 吴鹏, 赵玉梅, 陈冬梅, 等. 奈达铂与顺铂联合同期调强放疗治疗局部晚期鼻咽癌随机对照试验的Meta分析[J]. 肿瘤学杂志, 2019, 25(2): 107-115.
[28] Wang, K., Dong, J., He, S., Wang, X., Jiang, C., Hu, P., et al. (2019) Comparison of Weekly and Triweekly Cisplatin Regimens during Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma. BMC Cancer, 19, Article No. 482. [Google Scholar] [CrossRef] [PubMed]
[29] 王晓莉, 丁婷, 蒋美萍, 等. 诱导化疗后的Ⅲ-IVA期鼻咽癌患者同期化疗最适奈达铂总量的研究[J]. 昆明医科大学学报, 2022, 43(12): 66-74.
[30] Tang, Q., Liu, L., Qi, B., Guo, S., Luo, D., Sun, R., et al. (2021) Effect of Concurrent Chemoradiotherapy with Nedaplatin vs Cisplatin on the Long-Term Outcomes of Survival and Toxic Effects among Patients with Stage II to IVB Nasopharyngeal Carcinoma. JAMA Network Open, 4, e2138470. [Google Scholar] [CrossRef] [PubMed]
[31] Mu, X., Liu, H., Wu, J., Chen, S., Peng, X., Wang, J., et al. (2022) Induction versus Adjuvant Chemotherapy Combined with Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Retrospective Cohort Study. Aging, 14, 6727-6739. [Google Scholar] [CrossRef] [PubMed]
[32] Yang, S., Lin, S., Fu, Q., Cai, B., Kong, F., Huang, G., et al. (2015) The Effect of Adjuvant Chemotherapy on Survival in Patients with Residual Nasopharyngeal Carcinoma after Undergoing Concurrent Chemoradiotherapy. PLOS ONE, 10, e0120019. [Google Scholar] [CrossRef] [PubMed]
[33] Xu, T., Shen, C., Ou, X., He, X., Ying, H. and Hu, C. (2016) The Role of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma with Bulky Neck Lymph Nodes in the Era of IMRT. Oncotarget, 7, 21013-21022. [Google Scholar] [CrossRef] [PubMed]

为你推荐